Please assess the completion status of the following clinical trial:

Trial Title: MGR001 / Advair Diskus Local Equivalence Study in Asthma

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE3
- Number of Arms: 3.0

Eligibility Criteria:
Key inclusion criteria include:~* Male or female subjects aged ≥18 years. Females may be of either childbearing or non-childbearing potential~* Physician diagnosed history of asthma for at least 12 weeks prior to screening~* pre-bronchodilator FEV1 60-85% at screening and other specified visits~* Post-bronchodilator reversibility \>/=12%~* Non-smokers and prior smokers with no history of smoking within the past 12 months prior to screening and a total smoking history of ≤10 pack-years~* Subjects able to discontinue asthma medications for the duration of the study and be maintained using albuterol as required~* Body mass index between 18-40 kg/m2 inclusive~Key exclusion criteria include:~* Presence or recent history of any other active, severe, progressive, and/or uncontrolled clinical disease, eg, poorly controlled Type 1 or 2 diabetes, seizure disorder or epilepsy, cerebrovascular accident, significant cardiac conduction abnormalities~* Respiratory conditions other than asthma and allergic rhinitis, including but not limited to: severe nasal polyposis or chronic rhinosinusitis, chronic obstructive pulmonary disease, bronchiectasis, Churg-Strauss Disease, lung resection, pulmonary fibrosis (primary or secondary), pulmonary hypertension, cystic fibrosis, sarcoidosis~* History of life-threatening asthma, defined as a history of asthma episode(s) requiring intubation, and/or associated with hypercapnia; respiratory arrest or hypoxic seizures, asthma related syncopal episode(s)~* In patient hospitalization (not including ER visits) for an asthma exacerbation within the past year or during the run in period~* An asthma exacerbation requiring change in asthma therapy or oral/IV corticosteroids in the 3 months prior to screening~* History of seasonally unstable asthma where the season will coincide with the subject's participation in the study~* Use of prescription or non-prescription drugs, including beta blockers, tricyclic antidepressants, oral decongestants, benzodiazepines, digitalis, phenothiazines, monoamine oxidase inhibitors, etc~* Suspected hypersensitivity to the study drugs (including lactose) or severe milk protein allergy~* Clinically significant abnormalities in the screening ECG~* Evidence of alcohol or drug abuse or dependency within 6 months prior to screening

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- MGR001 (Type: EXPERIMENTAL): MGR001 administered two times per day by inhalation throughout the study
- Advair Diskus (Type: ACTIVE_COMPARATOR): Advair Diskus administered two times per day by inhalation throughout the study
- Placebo (Type: PLACEBO_COMPARATOR): Placebo for Advair Diskus and MGR001 administered two times per day by inhalation throughout the study

Based on this trial design, predict the completion outcome and termination type (if applicable).